摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-[1-(2-acetylbenzoyl)-4-piperidinyl]-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-1-quinolinyl]-1-(1-indol-3-ylmethyl)-2-oxoethyl]propanamide | 333953-41-6

中文名称
——
中文别名
——
英文名称
3-[1-(2-acetylbenzoyl)-4-piperidinyl]-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-1-quinolinyl]-1-(1-indol-3-ylmethyl)-2-oxoethyl]propanamide
英文别名
3-[1-(2-acetylbenzoyl)piperidin-4-yl]-N-[(2R)-1-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-2H-quinolin-1-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]propanamide
3-[1-(2-acetylbenzoyl)-4-piperidinyl]-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-1-quinolinyl]-1-(1-indol-3-ylmethyl)-2-oxoethyl]propanamide化学式
CAS
333953-41-6
化学式
C40H46ClN5O4
mdl
——
分子量
696.289
InChiKey
FIZYPQRZYVAUHL-XVODIUIHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.6
  • 重原子数:
    50
  • 可旋转键数:
    11
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    106
  • 氢给体数:
    2
  • 氢受体数:
    5

文献信息

  • AMINE DERIVATIVES
    申请人:Tadeka Chemical Industries, Ltd.
    公开号:EP1227090A1
    公开(公告)日:2002-07-31
    A compound of the formula:    wherein X and X' are the same or different, and each represents a hydrogen atom, a fluorine atom, a chlorine atom or an amino optionally having substituents, and at least one of X and X' represents a fluorine atom, a chlorine atom or an amino optionally having substituents; R1 and R2 represent a hydrogen atom or C1-6 alkyl optionally having substituents, or R1 and R2, together with the adjacent nitrogen atom, form a nitrogen-containing heterocyclic ring optionally having substituents; Y and Q are the same or different, and each represents a bond or a spacer having a main chain of 1 to 6 atoms; ... represents a single bond or a double bond; T1 and T2 are the same or different, and each represents C(R9) (R9 represents a hydrogen atom, a hydroxy or C1-6 alkyl) or N, when each of the adjacent ... is a single bond, and C when the adjacent ... is a double bond; and Ar represents an aromatic group optionally having substituents, a C3-9 cycloalkyl group optionally having substituents, a 3 to 9-membered saturated heterocyclic group optionally having substituents, a hydrogen atom or a halogen atom; provided that 6-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline; 6-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline and 1-benzoyl-N-[(R)-2-[6-chloro-3-[(N,N-dimethylamino)methyl]-1,2,3,4-tetrahydroquinolin-1-yl]-1-[3-(indol-3-yl)propanoyl]-4-piperidinecarboxamide are excluded; a salt thereof or a prodrug thereof has an excellent somatostatin receptor binding inhibition action and is useful for preventing and/or treating diseases associated with somatostatin.
    式中的化合物 X和X'相同或不同,各自代表氢原子、原子、原子或可选具有取代基的基,且X和X'中至少有一个代表原子、原子或可选具有取代基的基; R1 和 R2 代表氢原子或任选具有取代基的 C1-6 烷基,或 R1 和 R2 与相邻的氮原子一起形成任选具有取代基的含氮杂环; Y 和 Q 相同或不同,各自代表主链为 1 至 6 个原子的键或间隔物; 代表单键或双键; T1 和 T2 相同或不同,当相邻......中的每一个为单键时,各自代表 C(R9)(R9 代表氢原子、羟基或 C1-6 烷基)或 N,当相邻......中的每一个为双键时,各自代表 C;以及 Ar 代表任选具有取代基的芳香基、任选具有取代基的 C3-9 环烷基、任选具有取代基的 3-9 元饱和杂环基、氢原子或卤素原子;条件是 6--3-(R,S)-(N,N-二甲基基)甲基-1-[3-(吲哚-3-基)-2-[(R)-(4-苯基哌嗪-1-基)羰基基]丙酰基]-1,2,3,4-四氢喹啉;6--3-(R,S)-(N,N-二甲基基)甲基-1-[3-(吲哚-3-基)-2-[(R)-4-(2-氧代-2,3-二氢-1H-苯并咪唑-1-基)哌啶甲酰基]丙酰基]-1,2,3,4-四氢喹啉不包括 1-苯甲酰基-N-[(R)-2-[6--3-[(N,N-二甲基基)甲基]-1,2,3,4-四氢喹啉-1-基]-1-[3-(吲哚-3-基)丙酰基]-4-哌啶甲酰胺;其盐或其原药具有优异的抑制体生长抑素受体结合的作用,可用于预防和/或治疗与体生长抑素相关的疾病。
查看更多